Immune suppression is a known risk
factor for developing lymphomas based on the higher incidence of
lymphoma in persons receiving drugs to prevent rejection of
transplanted organs from donors.
It's also a known consequence of disease
progression. The tumor cells seem to make substances that dampen or
distort immune function, or the malignant cells may accumulate in
organs involved in immune cell development or maturation, such as
the bone marrow, spleen, lymph nodes.
Immune suppression is also a common side effect of standard treatments,
an effect with is generally reversible with time.
-[associated with NHL progression] as a negative regulator
of the immune system: high concentrations of the protein inhibit
in vitro generation of functional dendritic cells.
Blood. 2003 Jan
16 PMID: 12531797
Th1/Th2 cytokine expression and its relationship with tumor
growth in B cell non-Hodgkin's lymphoma (NHL).
Leuk Lymphoma. 2002
The Prevalence of Blastocystis Hominis in Immunosuppressed
Pure red cell aplasia due to parvovirus following treatment
with CHOP and rituximab for B-cell lymphoma.
Br J Haematol. 2002
Oct;119(1):125-7. PMID: 12358915
Frequency and type of serious infections in
Fludarabine-refractory B-cell chronic lymphocytic leukemia and
small lymphocytic lymphoma: implications for clinical trials in
this patient population. Cancer. 2002 Apr 1;94(7):2033-9. PMID:
Epstein-Barr virus-positive B-cell lymphoproliferative
disorders arising in immunodeficient patients previously treated
with fludarabine for low-grade B-cell neoplasms.
Am J Surg Pathol.
2002 May;26(5):630-6. PMID: 11979093
B-cell lymphomas involving the skin associated with hepatitis
C virus infection. Int J Dermatol. 2002 Sep;41(9):577-82. PMID:
12358827 - PubMed